Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source updated2026-09-25Last update listed in the registry record
Version history
Changes to this trial
Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
· 2 fields changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression-free Survival as Assessed by BICR
Description: Time from randomization until the time of first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first
Time frame: Up to 24 months from enrollment of the last patient
Measure: Overall survival
Description: Time from randomization to death by any cause
Time frame: Up to 24 months from enrollment of the last patient
+ After
Measure: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Description: PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions.
Time frame: Up to 20 months
Measure: Overall Survival
Description: Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates.
Time frame: Up to 32 months
Trial